I.G. Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

I.G. Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-19,000	Closed	-$962K	–	625
2016 Q3	$962K	Sell	19,000 -5,000	-21%	-$249K	﹤0.01%	659
2016 Q2	$1.09M	Sell	24,000 -33,000	-58%	-$1.52M	﹤0.01%	635
2016 Q1	$2.25M	Buy	57,000 +12,000	+27%	+$476K	0.01%	492
2015 Q4	$2.55M	Buy	+45,000	New	+$2.29M	0.01%	451

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

I.G. Investment Management's NBIX Position: Q4 2016 in Review

I.G. Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 19,000 shares — an estimated $962K sold.

I.G. Investment Management first reported a position in NBIX in Q4 2015 and held it in 4 quarters. The position peaked at $2.55M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

I.G. Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
I.G. Investment Management sold 19,000 Neurocrine Biosciences shares in Q4 2016, an estimated $962K.
I.G. Investment Management first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 4 quarters.
I.G. Investment Management's Neurocrine Biosciences position peaked at $2.55M in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on I.G. Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.